Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.60 |
| ▸ | CTSK | P43235 | 5/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896150 | 1.00 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL30753714 | 1.00 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL3997764 | 1.00 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4893696 | 0.90 | CTSS (0.50) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4663069 | 0.90 | CTSS (0.57) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4922934 | 0.87 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL7029037 | 0.87 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4922943 | 0.87 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL755370 | 0.87 | CTSS (0.45) | CTSSCTSK | |
| SCHEMBL18526772 | 0.87 | CTSS (0.45) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486762-A | Novel compound and use method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-02 | — | — | CN | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | CTSS 3395/4885CTSK 990/4885ATM 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.